Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Edesa Biotech Inc(EDSA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for EDSA
09/25/2026: EDSA (1-star) is currently NOT-A-BUY. Pass it for now.
Edesa Biotech Inc is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immune-related conditions. Its main strengths include a targeted pipeline consisting of assets like EB05 and EB01, supported by a lean operating model that prioritizes research efficiency. The investment story centers on the potential for successful clinical outcomes to drive value through regulatory approval or strategic partnerships. However, the company faces significant risks including clinical failure, the need for continuous financing in a competitive biotech market, and heavy reliance on future success for revenue. It is best suited for growth-oriented investors who can tolerate high risk and monitor clinical milestones closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to drug development but lacks established growth metrics. |
| Momentum investor | Mixed fit | This style is only appropriate during positive clinical data releases or major partnership announcements. |
| Value investor | Weak fit | The lack of consistent earnings and revenue makes traditional value metrics difficult to apply. |
| Dividend investor | Weak fit | Edesa does not pay dividends and focuses all capital on research and development. |
| Low-risk investor | Weak fit | The clinical-stage nature of the business inherently involves high volatility and risk of capital loss. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to news regarding clinical trial milestones. |
| Valuation risk | Medium / high | Valuations for pre-revenue biotech companies are speculative and subject to rapid adjustments. |
| Competition risk (Large Pharma) | High | Edesa competes with well-capitalized firms that have dominant market positions. |
| Business quality | Medium | As a clinical-stage entity, the business is purely R&D-focused without the stability of commercial operations. |
| Dividend income | Low / none | Investors should not expect income from this equity. |
| Execution risk | High | Success depends entirely on the company's ability to navigate complex clinical and regulatory hurdles. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -47.79% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.85M USD | Price to earnings Ratio - | 1Y Target Price 16.33 |
Price to earnings Ratio - | 1Y Target Price 16.33 | ||
Volume (30-day avg) 73.8K shares | Beta 1.06 | 52 Weeks Range 0.72 - 20.32 | Updated Date 09/25/2026 |
52 Weeks Range 0.72 - 20.32 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Clinical-stage research and development for EB05 and EB01. | The company does not yet sell products and relies on funding to develop medicines. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 0.18 | Enterprise Value 37.64M | Price to Sales(TTM) 130462.29 |
Enterprise Value 37.64M | Price to Sales(TTM) 130462.29 | ||
Enterprise Value to Revenue 140491.25 | Enterprise Value to EBITDA -1.25 | Shares Outstanding 9.64M | Shares Floating 7.19M |
Shares Outstanding 9.64M | Shares Floating 7.19M | ||
Percent Insiders 13.5 | Percent Institutions 37.44 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Edesa Biotech Inc
Exchange NASDAQ | Headquarters Markham, ON, Canada | ||
IPO Launch date 2015-11-05 | CEO, Company Secretary & Director Dr. Pardeep Nijhawan FRCPC, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.edesabiotech.com |
Full time employees 17 | Website https://www.edesabiotech.com | ||
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.